Status:
COMPLETED
Breast Screening Atypia and Subsequent Development of Cancer in England
Lead Sponsor:
University of Warwick
Collaborating Sponsors:
University Hospitals Coventry and Warwickshire NHS Trust
King's College London
Conditions:
Breast Cancer
Eligibility:
FEMALE
47-73 years
Brief Summary
During breast screening, atypical epithelial proliferations (atypia) can be detected. These are not cancer, but may mean that a woman is more likely to develop breast cancer in the future. This study ...
Detailed Description
In England, breast cancer screening is offered every three years to women aged 50 to 70. In an increasing number of women atypical epithelial proliferations (atypias) are detected. Atypias are a heter...
Eligibility Criteria
Inclusion
- Diagnosis of epithelial atypia (ADH (including AIDEP), LISN (both ALH and LCIS) and FEA) in the Sloane database between 1st January 2003 and 30th June 2018
Exclusion
- bilateral primary cases
- the "best prognosis" atypia of the bilateral primaries
- atypia with co-existing DCIS
- pleomorphic LCIS (as these are managed akin to DCIS)
- unknown type of atypia
- cases not from England
- patients without follow-up until 31 December 2018
Key Trial Info
Start Date :
December 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
3238 Patients enrolled
Trial Details
Trial ID
NCT05402436
Start Date
December 1 2021
End Date
December 30 2023
Last Update
January 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Univesity of Warwick
Coventry, Warwickshire, United Kingdom, CV47AL